Featured Research

from universities, journals, and other organizations

Researchers characterize 'epigenetic fingerprints' of 1,628 people

Date:
June 2, 2011
Source:
IDIBELL-Bellvitge Biomedical Research Institute
Summary:
Researchers have identified the "epigenetic fingerprints" of 1,628 people -- healthy volunteers in addition to patients suffering from common diseases, such as cancer, and cardiovascular and neurodegenerative diseases.

Until a decade, it was believed that differences between people were due solely to the existence of genetic changes, which are alterations in the sequence of our genes. Discoveries made during the last 10 years show that beings with the same genetics, such as human twins and cloned animals, may have different characteristics and disease due to epigenetic changes.

Epigenetics involves chemical signatures that are added to DNA and proteins that package it, to regulate their activity. The more recognized epigenetic brand is DNA methylation, a process based on the addition of a methyl chemical group into a part of our genetic puzzle. Therefore, while the genetic is like the alphabet, epigenetics is like the punctuation marks of a text.

Researcher Manel Esteller, director of the Epigenetics and Cancer Biology Program of the Bellvitge Biomedical Research Institute (IDIBELL), professor at the University of Barcelona and ICREA researcher, has coordinated a work that identifies the "epigenetic fingerprints" of 1,628 people -- healthy volunteers in addition to patients suffering from common diseases, such as cancer, and cardiovascular and neurodegenerative diseases. The findings are published in the scientific journal Genome Research.

'Photo finish'

"The study analyses thousands of sites of DNA methylation in this great set of physiological and pathological tissues, it would be like a photo finish in a race that teaches you the epigenome of the individual at a particular time" says Dr. Esteller.

The results from the research provide understanding of many processes of the human body and how these processes lead to disease. The IDIBELL researcher says that "in the case of cancer, the study shows that all human tumours suffer epigenetic inactivation of cancer-protective genes and also tumour cells lose their epigenetic memory and can not remember what healthy tissue was."

Dr. Esteller explains how these changes related to the cancerous disease are not instantaneous but gradually accumulate with aging of our bodies. The changes are different from those in dementia and other autoimmune diseases with different epigenomes.

A very interesting result for its potential applicability is that we could know the primary tumour of metastases with unknown origin: "If we know the tumour from which emerged these cells, we can provide the most appropriate therapy for a patient and improve his or her survival."

The investigation involves several IDIBELL researchers linked to IDIBELL's scientific partners: the Catalan Institute of Oncology, the University of Barcelona and the Bellvitge University Hospital.

Bellvitge Institute for Biomedical Research (IDIBELL) is a research center created in 2004 with the participation of the Bellvitge University Hospital, the Catalan Institute of Oncology, the University of Barcelona, and the Institute of Image Diagnosis. IDIBELL is integrated in Biopol'H, the health and scientific park of l'Hospitalet de Llobregat-Barcelona.


Story Source:

The above story is based on materials provided by IDIBELL-Bellvitge Biomedical Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. A. F. Fernandez, Y. Assenov, J. Martin-Subero, B. Balint, R. Siebert, H. Taniguchi, H. Yamamoto, M. Hidalgo, A.-C. Tan, O. Galm, I. Ferrer, M. Sanchez-Cespedes, A. Villanueva, J. Carmona, J. V. Sanchez-Mut, M. Berdasco, V. Moreno, G. Capella, D. Monk, E. Ballestar, S. Ropero, R. Martinez, M. Sanchez-Carbayo, F. Prosper, X. Agirre, M. F. Fraga, O. Grana, L. Perez-Jurado, J. Mora, S. Puig, J. Prat, L. Badimon, A. A. Puca, S. J. Meltzer, T. Lengauer, J. Bridgewater, C. Bock, M. Esteller. A DNA methylation fingerprint of 1,628 human samples. Genome Research, 2011; DOI: 10.1101/gr.119867.110

Cite This Page:

IDIBELL-Bellvitge Biomedical Research Institute. "Researchers characterize 'epigenetic fingerprints' of 1,628 people." ScienceDaily. ScienceDaily, 2 June 2011. <www.sciencedaily.com/releases/2011/06/110602081842.htm>.
IDIBELL-Bellvitge Biomedical Research Institute. (2011, June 2). Researchers characterize 'epigenetic fingerprints' of 1,628 people. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/06/110602081842.htm
IDIBELL-Bellvitge Biomedical Research Institute. "Researchers characterize 'epigenetic fingerprints' of 1,628 people." ScienceDaily. www.sciencedaily.com/releases/2011/06/110602081842.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins